{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_name": "nvl330"
  },
  "asset": {
    "name": "NVL-330",
    "ticker": "NUVL",
    "modality": "Small molecule kinase inhibitor",
    "stage": "Phase 1",
    "one_liner": "HER2-selective, EGFR-sparing TKI designed for superior CNS penetration and tolerability in HER2+ cancers",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "HER2",
    "full_name": "Human Epidermal Growth Factor Receptor 2 (ERBB2)",
    "class": "Receptor Tyrosine Kinase",
    "pathway": "HER2 mutation/amplification → constitutive signaling → tumor growth",
    "biology": {
      "simple_explanation": "HER2 is a receptor tyrosine kinase that when mutated or amplified drives tumor growth in multiple cancers including NSCLC. HER2 exon 20 insertions and point mutations represent distinct oncogenic drivers requiring targeted therapy.",
      "prevalence": "2-4% of NSCLC (mutations); additional patients with amplification",
      "mutation_types": "Exon 20 insertions (YVMA, VC, GSP), point mutations (S310F, R678Q, L755S, etc.)"
    },
    "why_good_target": {
      "clinical_validation": "T-DXd (ADC) and zongertinib (TKI) approved for HER2+ NSCLC",
      "unmet_need": [
        "T-DXd has 30% serious AEs including ILD risk",
        "Zongertinib may have suboptimal CNS penetration",
        "Other HER2 TKIs have variable EGFR inhibition causing rash/diarrhea"
      ]
    }
  },
  "indications": {
    "lead": {
      "name": "HER2+ NSCLC",
      "stage": "Phase 1",
      "rationale": "Validated target with approved therapies but significant tolerability limitations"
    },
    "expansion": [
      {
        "name": "HER2+ solid tumors",
        "stage": "Phase 1",
        "rationale": "Broad applicability across HER2-driven cancers"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "HEROEX-1 (NCT06521554)",
    "trial_design": {
      "phase": "Phase 1a/1b",
      "design": "BOIN dose-escalation",
      "enrollment": "Up to ~120 patients planned"
    },
    "populations": {
      "phase_1": {
        "n": "Enrolling",
        "description": "HER2 mutation or amplification solid tumors"
      }
    },
    "current_status": "BOIN dose-escalation ongoing; no clinical efficacy data yet"
  },
  "preclinical_data": {
    "selectivity": {
      "her2_vs_egfr": "HER2-selective, EGFR-sparing design",
      "clinical_relevance": "Avoids EGFR-related rash and diarrhea"
    },
    "mutation_coverage": {
      "her2_amplification": "Active",
      "exon_20_insertions": "Active against YVMA, VC, GSP",
      "point_mutations": "Active against S310F, R678Q, L755S, others"
    },
    "cns_penetration": {
      "kpuu": "~0.15 (superior to zongertinib in rat studies)",
      "preclinical_efficacy": "84% tumor reduction in zongertinib-progressing intracranial model"
    }
  },
  "catalysts": [
    {
      "event": "Phase 1 dose escalation data",
      "timing": "2026-2027",
      "importance": "high",
      "what_to_watch": "Safety, tolerability, and early efficacy signals"
    }
  ],
  "competitive_landscape": {
    "approved_her2_therapies": [
      {
        "drug": "T-DXd (trastuzumab deruxtecan)",
        "company": "Daiichi/AstraZeneca",
        "efficacy": "58% ORR, 8.7 months mDOR",
        "limitation": "30% serious AEs, ILD risk, IV administration"
      },
      {
        "drug": "zongertinib",
        "company": "Novartis",
        "status": "Accelerated approval 2025",
        "limitation": "May have suboptimal CNS penetration"
      }
    ],
    "nvl330_potential_advantages": [
      "EGFR-sparing for improved tolerability",
      "Superior preclinical CNS penetration (Kp,uu ~0.15)",
      "Oral TKI convenience vs IV ADC"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "Early stage - higher risk",
    "peak_sales_estimate": "TBD - depends on differentiation vs T-DXd and zongertinib",
    "key_risks": [
      "Early Phase 1 with no clinical efficacy data",
      "Established competition (T-DXd, zongertinib)",
      "Differentiation must be proven clinically"
    ]
  },
  "market_opportunity": {
    "her2_nsclc_prevalence": "2-4% of NSCLC (~5,000-10,000 US patients annually)",
    "broader_her2_opportunity": "Additional solid tumors with HER2 alterations",
    "key_insight": "Third pipeline asset provides optionality beyond ROS1/ALK"
  }
}
